Drug intelligence / Profile preview

iHSC013

Development stage: Preclinical
Lead developer: Cell Inspire Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iHSC013 is an induced pluripotent stem cell (iPSC)-derived hematopoietic stem cell (HSC) therapy developed by Cell Inspire Biotechnology. The cells are genetically engineered to express CD16 (FcγRIIIa) and a secreted form of interleukin-15 (sIL-15). The expression of CD16 is intended to enhance antibody-dependent cellular cytotoxicity (ADCC) potential, while the secretion of IL-15 provides autocrine or paracrine support to maintain and stimulate immune effector functions. This therapy is currently in the preclinical stage of development for oncology applications.

Beyond the preview

Go deeper on iHSC013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iHSC013.

Explore the full profile